Pulmonary Arterial Hypertension clinical trials at UC Irvine
3 in progress, 1 open to eligible people
Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
open to eligible people ages 18-100
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
Orange, California and other locations
Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Sorry, accepting new patients by invitation only
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Orange, California and other locations
Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
Sorry, in progress, not accepting new patients
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants. Part B: A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.
Costa Mesa, California and other locations
Our lead scientists for Pulmonary Arterial Hypertension research studies include Bassam Yaghmour.
Last updated: